CAMP4 and GSK have entered into a strategic collaboration to accelerate the development of novel antisense oligonucleotides for neurodegenerative and renal diseases.
CAMP4 will receive a $17.5 million upfront payment and potential milestone-based payments and royalties from GSK.
The collaboration aims to identify and develop ASO drug candidates for multiple gene targets relevant to neurodegenerative and kidney diseases.
Strategic Collaboration with GSK
CAMP4 and GSK have partnered to leverage CAMP4's RAP Platform® for the development of ASO drug candidates.
Financial Incentives
CAMP4 to receive $17.5 million upfront and additional milestone-based payments along with tiered royalties from GSK.
Focus on Neurodegenerative and Renal Diseases
The collaboration focuses on developing ASO therapeutics for diseases characterized by protein under-expression.
Utilization of RAP Platform®
CAMP4 will utilize its proprietary RAP Platform® to identify regRNAs controlling gene expression for ASO candidate development.
- The collaboration signifies a significant step towards advancing RNA-based therapeutic discoveries for challenging diseases.
- CAMP4's expertise in upregulating gene expression combined with GSK's resources in therapeutic oligonucleotides holds promise for innovative treatments.
- The focus on neurodegenerative and renal diseases highlights the commitment to addressing critical medical needs through genomic approaches.
The partnership between CAMP4 and GSK opens new possibilities for advancing treatments in the field of genetic diseases, with a specific focus on neurodegenerative and renal conditions. The collaboration represents a strategic move towards developing transformative medicines for patients in need.